Figure 2. HR for outcomes of interest respect by cirrhosis. Mortality: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, anaemia. Rejection/graft loss: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, BMI, diabetes, cardio-cerebrovascular diseases. Infections: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD. Diabetes: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, thyroid disorders, anaemia, depression, BMI. Cancer: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, anticoagulants/antiplatelet. MACE: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, age (donor), diabetes, BMI, anticoagulants/antiplatelet. Use of LMAs: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, Charlson index, depression, diabetes. Note: TAC: Tacrolimus; BMI: body mass index; IR: incidence rate; LMAs: lipid-modifying agents; MACE: major adverse cardiovascular events; MELD: model for end-stage liver disease; mTORi:molecular target of rapamycin inhibitors.